RJ
Therapeutic Areas
Puma Biotechnology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NERLYNX® (neratinib, oral) | HER2-positive early-stage breast cancer (extended adjuvant) | Approved |
| NERLYNX® (neratinib) | HER2-positive metastatic breast cancer | Approved/Commercial |
| Alisertib | Small Cell Lung Cancer (SCLC) | Phase 2 |
| PB272 (neratinib, intravenous) | Cancer | Not Disclosed |
| PB357 | Cancer | Not Disclosed |
Leadership Team at Puma Biotechnology
AH
Alan H. Auerbach
Chief Executive Officer, President, and Chairman of the Board
BA
Brian A. Leyland-Jones
Chief Medical Officer
SK
Samuel K. (Sam) Ruch
Executive Vice President, General Counsel, and Corporate Secretary
JP
James P. (Jim) O'Brien
Executive Vice President and Chief Financial Officer